Prior studies have demonstrated the feasibility of MDM2 inhibition as a therapeutic strategy in ALL, predominantly focused upon specific subtypes including KMT2A-rearranged [34] and ETV6::RUNX1 translocated ALL [35]. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.